Mr. David Levine reports

DRI HEALTHCARE TRUST ANNOUNCES ACQUISITION OF A ROYALTY INTEREST IN THE WORLDWIDE SALES OF OMIDRIA(TM) FOR INTRACAMERAL USE DURING CATARACT SURGERY OR INTRAOCULAR LENS REPLACEMENT

A wholly owned subsidiary of DRI Healthcare Trust has acquired a royalty interest in Omidria from Omeros Corp. for a purchase price of $125-million (U.S.).

Omidria was approved by the U.S. Food and Drug Administration in May, 2014, and the European Medicines Agency in July, 2015, for intracameral use during cataract surgery or intraocular lens replacement to maintain pupil dilation and reduce postoperative pain. Omidria is marketed by Rayner Surgical, one of the world leaders in the field of cataract surgery with operations in over 80 countries worldwide.

"We are pleased to announce our partnership with Omeros and look forward to continuing to work with their team," said Behzad Khosrowshahi, chief executive officer of DRI Healthcare Trust. "Adding Omidria to our portfolio represents a significant and strategic transaction for DRI. It is expected to immediately contribute meaningful and growing cash flows to our portfolio. With this transaction DRI has now deployed $184.5-million (U.S.) over three transactions so far in 2022."

Royalties will be received by DRI monthly and will be subject to annual caps ($1.67-million (U.S.) in aggregate for the four months from Sept. 1, 2022, through Dec. 31, 2022; $13-million (U.S.) for 2023; $20-million (U.S.) for 2024; $25-million (U.S.) for each of 2025 through 2028 (inclusive); $26.25-million (U.S.) for 2029; and $27.5-million for 2030 with no entitlement thereafter). According to Omeros's public filings, in the first six months of 2022 Omeros collected $31.1-million under the royalty being acquired.

About Omidria

Omidria is a bisulphite-free and preservative-free product that is indicated for intracameral irrigation during cataract surgery to maintain pupil dilation and reduce postoperative pain. Sufficient mydriasis during cataract surgery is critical to a successful surgical outcome by providing visualization of the surgical field, a good red reflex and adequate room for intraocular manipulation of surgical instruments. Unlike preoperatively administered topical drugs for mydriasis and pain management that are washed out of the eye by irrigation solution used during intraocular lens replacement, intracameral irrigation of Omidria exposes target tissues to consistent concentrations of phenylephrine and ketorolac throughout the entire procedure thereby maintaining intraoperative mydriasis and reducing postoperative pain.

Omidria requires no modification to the current surgical procedure offering an easy addition to current treatments and surgical technique, and unlike products from unregistered compounding facilities, offers the added benefit of uniform production under good manufacturing practices. There are no other intracameral administered mydriatic or pain management products in development.

Conference call dial-in and webcast

DRI will hold a conference call today at 10 a.m. ET to discuss the transaction. A slide presentation will accompany the call and can be accessed on-line through the webcast. All interested parties may join the conference call by dialling 1-888-664-6392 or 416-764-8659 approximately 15 minutes prior to the call to secure a line.

A question-and-answer session will follow the conference call, at which time the operator will provide instructions for submitting questions.

A live webcast of the conference call, including a slide presentation, will be available on-line. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on the Trust's website following the call date.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc., the pioneer in global pharmaceutical royalty monetization with a more-than-30-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since its founding in 1989, DRI Capital has deployed more than $2-billion (U.S.), acquiring more than 60 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in United States dollars under the symbol DHT.U.

We seek Safe Harbor.